Expander-2 -Benign Prostatic Hyperplasia (BPH)
Struggling with lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)? Approximately, 60% of men over the age of 60 and up to 80% of men overall, will eventually develop BPH with LUTS, of which 30% will require treatment¹.
Benign Prostatic Hyperplasia (BPH) is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to Lower Urinary Tract Symptoms (LUTS).
- Common LUTS related to BPH include:
- Poor or intermittent urine stream
- Difficulty to urinate
- Sudden urge to urinate
- Waking up frequently at night to urinate
- Having to urinate frequently
- Feeling of incomplete bladder emptying
Trial participants will be required to go off their BPH medications for the duration of the trial (under the supervision of a doctor).
The Expander-2 clinical trial objective is to evaluate the safety and efficacy of the Urocross™ System and the procedure to treat patients with symptomatic BPH. The Expander-2 Trial is a blinded study, meaning that participants will not be told whether they are receiving the investigational treatment or not. Participants who do not receive the investigational treatment will be eligible to cross over to the investigational treatment group after the unblinding (after 3 months).
Trial participants will be required to attend follow-up appointments to evaluate their progress at 1 week* and 2 weeks, at 1-, 3-, and 6- months, as well as 1-, 2-, and 3- years post-treatment.